X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39121) 39121
Book Chapter (415) 415
Newsletter (213) 213
Newspaper Article (52) 52
Book / eBook (14) 14
Magazine Article (11) 11
Dissertation (7) 7
Trade Publication Article (7) 7
Conference Proceeding (4) 4
Publication (2) 2
Web Resource (2) 2
Book Review (1) 1
Journal / eJournal (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (33546) 33546
humans (32549) 32549
life sciences & biomedicine (29920) 29920
oncology (21332) 21332
female (17237) 17237
male (15379) 15379
middle aged (13521) 13521
lung neoplasms - genetics (12820) 12820
carcinoma, non-small-cell lung - genetics (12184) 12184
lung cancer (11996) 11996
aged (11640) 11640
cancer (10956) 10956
lung neoplasms - pathology (10416) 10416
carcinoma, non-small-cell lung - pathology (9171) 9171
cell line, tumor (8657) 8657
prognosis (8623) 8623
adult (8478) 8478
tumors (7900) 7900
mutation (7218) 7218
lung cancer, non-small cell (7007) 7007
gene expression (6997) 6997
carcinoma, non-small-cell lung - drug therapy (6775) 6775
lung neoplasms - drug therapy (6669) 6669
metastasis (6611) 6611
genetic aspects (6543) 6543
animals (6360) 6360
research (5713) 5713
gene expression regulation, neoplastic (5709) 5709
lung neoplasms - metabolism (5601) 5601
apoptosis (5530) 5530
analysis (5364) 5364
proteins (5230) 5230
aged, 80 and over (5183) 5183
chemotherapy (5078) 5078
carcinoma, non-small-cell lung - metabolism (5005) 5005
immunohistochemistry (4959) 4959
cell biology (4898) 4898
medical prognosis (4864) 4864
care and treatment (4766) 4766
non-small cell lung carcinoma (4563) 4563
mice (4435) 4435
cancer therapies (4429) 4429
neoplasm staging (4405) 4405
kinases (4296) 4296
health aspects (4190) 4190
development and progression (4156) 4156
non-small cell lung cancer (4147) 4147
research article (4125) 4125
squamous cell carcinoma (4109) 4109
cell proliferation (4025) 4025
patients (3972) 3972
medicine (3859) 3859
pathology (3634) 3634
science & technology - other topics (3631) 3631
multidisciplinary sciences (3587) 3587
signal transduction (3390) 3390
carcinoma, squamous cell - genetics (3231) 3231
studies (3226) 3226
receptor, epidermal growth factor - genetics (3193) 3193
metastases (3159) 3159
biochemistry & molecular biology (3127) 3127
biomarkers (3096) 3096
science (3013) 3013
biomarkers, tumor - genetics (2963) 2963
antineoplastic agents - therapeutic use (2894) 2894
genes (2888) 2888
cell cycle (2876) 2876
lung neoplasms - mortality (2832) 2832
carcinoma, squamous cell - pathology (2772) 2772
treatment outcome (2691) 2691
respiratory system (2682) 2682
cell growth (2653) 2653
survival analysis (2631) 2631
carcinoma, non-small-cell lung - mortality (2586) 2586
polymerase chain reaction (2586) 2586
medicine, research & experimental (2483) 2483
research & experimental medicine (2482) 2482
micrornas - genetics (2429) 2429
adenocarcinoma - genetics (2419) 2419
epidermal growth factor (2414) 2414
antineoplastic agents - pharmacology (2365) 2365
surgery (2339) 2339
cancer research (2320) 2320
respiratory tract diseases (2311) 2311
breast cancer (2307) 2307
deoxyribonucleic acid--dna (2301) 2301
medical research (2282) 2282
carcinoma (2263) 2263
risk factors (2244) 2244
survival (2189) 2189
retrospective studies (2154) 2154
mice, nude (2147) 2147
nsclc (2103) 2103
hepatocellular carcinoma (2101) 2101
adenocarcinoma (2098) 2098
disease-free survival (2089) 2089
liver cancer (2051) 2051
colorectal cancer (2033) 2033
medicine & public health (1982) 1982
protein kinase inhibitors - therapeutic use (1980) 1980
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (7) 7
Gerstein Science - Stacks (5) 5
Online Resources - Online (3) 3
Gerstein Science - Periodical Stacks (1) 1
Mt Sinai Hospital - Online (1) 1
Scarborough Hospital - Birchmount (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Toronto East General Hospital - Online (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (39326) 39326
Chinese (622) 622
Japanese (121) 121
French (109) 109
German (69) 69
Russian (47) 47
Portuguese (36) 36
Spanish (24) 24
Polish (17) 17
Norwegian (12) 12
Czech (8) 8
Hungarian (7) 7
Italian (5) 5
Korean (4) 4
Croatian (2) 2
Danish (2) 2
Dutch (2) 2
Slovak (2) 2
Turkish (2) 2
Arabic (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation (T790M... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
8.